Pharmacological
profiles
of
aminoindanes,
piperazines,
and
pipradrol
derivatives
Linda D Simmler,a Anna Rickli,a York Schramm,b Marius C. Hoener,c and
Matthias E. Liechtia
a
Psychopharmacology Research, Division of Clinical Pharmacology and Toxicology,
Department of Biomedicine, University Hospital Basel and University of Basel, Basel,
Switzerland; bDepartment of Chemistry, University of Basel, Basel, Switzerland;
c
Neuroscience Research, Pharmaceuticals Division, F. Hoffmann-La Roche Ltd,
Basel, Switzerland
* Corresponding author: Dr. Matthias E. Liechti, Division of Clinical Pharmacology
and Toxicology, University Hospital Basel, Hebelstrasse 2, Basel, CH-4031,
Switzerland. Tel: +41 61 328 68 68; Fax: +41 61 265 45 60; E-mail:
matthias.liechti@usb.ch (M.E. Liechti)
Word counts: Abstract: 235; References: 76; Tables: 2; Figures: 3.
1
ABSTRACT
Aminoindanes, piperazines, and pipradrol derivatives are novel psychoactive
substances
found
in
“Ecstasy”
tablets
as
replacements
for
3,4-
methylenedioxymethamphetamine (MDMA) or substances sold as “ivory wave.” The
pharmacology of these MDMA- and methylphenidate-like substances is poorly
known.
We
characterized
the
methylenedioxy-2-aminoindane
aminoindane
(2-AI),
the
pharmacology
(MDAI),
piperazines
of
the
5-iodoaminoindane
aminoindanes
(5-IAI),
meta-chlorophenylpiperazine
and
5,62-
(m-CPP),
trifluoromethylphenylpiperazine (TFMPP), and 1-benzylpiperazine (BZP), and the
pipradrol derivatives desoxypipradrol (2-diphenylmethylpiperidine [2-DPMP]),
diphenylprolinol (diphenyl-2-pyrrolidinemethanol [D2PM]), and methylphenidate.
We investigated norepinephrine (NE), dopamine (DA), and serotonin (5hydroxytryptamine [5-HT]) uptake inhibition using human embryonic kidney 293
(HEK 293) cells that express the respective human monoamine transporters (NET,
DAT, and SERT). We also evaluated the drug-induced efflux of NE, DA, and 5-HT
from monoamine-preloaded cells and the binding affinity to monoamine transporters
and receptors, including trace amine-associated receptor 1 (TAAR1). 5-IAI and MDAI
preferentially inhibited the SERT and NET and released 5-HT. 2-AI interacted with
the NET. BZP blocked the NET and released DA. m-CPP and TFMPP interacted with
the SERT and serotonergic receptors. The pipradrol derivatives were potent and
selective catecholamine transporter blockers without substrate releasing properties.
BZP, D2PM, and 2-DPMP lacked serotonergic activity and TAAR1 binding, in
contrast to the aminoindanes and phenylpiperazines. In summary, all of the substances
were monoamine transporter inhibitors, but marked differences were found in their
2
DAT vs. SERT inhibition profiles, release properties, and receptor interactions. The
pharmacological profiles of D2PM and 2-DPMP likely predict a high abuse liability.
Keywords: Novel Psychoactive Substance, Monoamine, Transporter, Receptor
Abbreviations: 2-AI, 2-aminoindane; BZP, 1-benzylpiperazine; DA, dopamine;
DAT, dopamine transporter; D2PM, diphenyl-2-pyrrolidinemethanol; 2-DPMP,
desoxypipradrol or 2-diphenylmethylpiperidine; HEK, human embryonic kidney ; 5IAI, 5-iodoaminoindane; m-CPP, meta-chlorophenylpiperazine; MDAI, 5,6methylenedioxy-2-aminoindane; MDMA, 3,4-methylenedioxymethamphetamine; NE,
norepinephrine; NET, norepinephrine transporter; 5-HT, 5-hydroxytryptamine
(serotonin); SERT, serotonin transporter; TAAR, trace amine-associated receptor;
TFMPP, trifluoromethylphenylpiperazine.
3
1. Introduction
New psychoactive substances [1] are constantly emerging on the illicit drug
market. Many of these novel designer substances are amphetamine derivatives and
typically marketed as “bath salts”, “research chemicals” or “legal highs” via the
Internet [2]. Pharmacological information is typically not available for these newly
emerging designer substances. Interactions with the norepinephrine (NE), dopamine
(DA), and serotonin (5-hydroxytryptamine [5-HT]) transporters (NET, DAT, and
SERT, respectively) to block or release monoamines can be expected based on the
amphetamine-like core structure of many of these substances. In addition, chemical
modifications typically alter absolute or relative potencies at the NET and DAT
relative to the SERT or substrate release properties, thereby affecting stimulant-like
and reinforcing properties [3, 4]. Additional interactions with the 5-HT2A receptor
may result in hallucinogenic-like actions. Substances that predominantly act on the
NET and DAT have stimulant-like properties similar to amphetamine, whereas
substances that mostly act on the SERT may have more “empathogenic” properties
similar to 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) [4, 5]. Assessing
the in vitro pharmacological profiles of novel substances is a relatively rapid approach
for gaining a first impression of their potential clinical effects and toxicology, in
addition to user reports. Accordingly, the pharmacology of many novel designer
cathinones (“bath salts” and “research chemicals”) has recently been characterized in
vitro [4, 6-10]. The aim of the present study was to describe the effects on monoamine
uptake and release of novel psychoactive substances that are not cathinones, but have
been introduced into the illicit drug market as “legal highs” to typically mimic the
subjective effects of MDMA or amphetamine-type stimulants. Aminoindanes, such as
5,6-methylenedioxy-2-aminoindane (MDAI) and 5-iodoaminoindane (5-IAI), became
4
increasingly available over the Internet starting in 2010 as legal and, in the case of
MDAI, allegedly less-neurotoxic alternatives to MDMA [11-13]. Piperazines have
been used for more than a decade [14] and are commonly found in Ecstasy pills as
substitutes for MDMA [15, 16]. Toxicity associated with the use of “ivory wave,”
which contains the pipradrol derivative desoxypipradrol (2-diphenylmethylpiperidine
[2-DPMP]) or diphenylprolinol (diphenyl-2-pyrrolidinemethanol [D2PM]) was
increasingly reported starting in 2010 [17-19]. The present study investigated the
aminoindanes
2-aminoindane
(2-AI),
5-IAI,
and
MDAI,
the
piperazines
meta-chlorophenylpiperazine (m-CPP), trifluoromethylphenylpiperazine (TFMPP),
and 1-benzylpiperazine (BZP), and the pipradrol derivatives D2PM and 2-DPMP.
Similar data on MDMA and other novel psychoactive substances have previously
been published [4, 6]. We determined the potencies of the compounds to inhibit the
human NET, DAT, and SERT. We tested whether the compounds induce the
transporter-mediated release of NE, DA, and 5-HT and characterized the binding
affinities of the compounds for monoamine transporters, 1 and 2 adrenergic
receptors, dopamine D1-D3 receptors, 5-HT1A, 5-HT2A, and 5-HT2C receptors, the
histamine H1 receptor, and trace amine-associated receptor 1 (TAAR1). Most of the
substances examined herein were previously studied using rodent transporters, but
only a few were also studied using human transporters and receptors [7]. However,
more comprehensive analyses are needed at both human transporters and receptors
Similar data on novel designer cathinones and classic stimulants, including
amphetamine, methamphetamine, MDMA, and cocaine have previously been
obtained using identical methods [4, 6].
2. Methods
5
2.1. Chemicals
MDMA, methylphenidate, m-CPP, TFMPP, and BZP were supplied by
Lipomed (Arlesheim, Switzerland), and 5-IAI, 2-AI, 2-DPMP, and D2PM were
supplied by Cayman Chemicals (Ann Arbor, MI, USA) as racemic hydrochloride salts
(purity > 98.5%). MDAI was synthesized as a racemic hydrochloride salt in our
laboratory according to Nichols et al. [20]. Radiochemicals (3H-isotopes) were
obtained from Anawa (Wangen, Switzerland) or Perkin Elmer (Schwerzenbach,
Switzerland), with the exception of [3H]RO5166017, which was synthesized at Roche
(Basel, Switzerland).
2.2. Monoamine uptake transport inhibition
The inhibition of the NET, SERT, and DAT was assessed in human
embryonic kidney 293 (HEK 293) cells that stably expressed the human NET, SERT,
and DAT [21] as previously described in detail [22]. Cultured cells were detached and
resuspended in uptake buffer. We incubated the cells with various concentrations of
the test compounds and the vehicle control for 10 min and then added [ 3H]DA,
[3H]NE, and [3H]5-HT (5 nM final concentrations) to initiate the uptake transport of
the labeled monoamines at room temperature. Uptake was stopped after 10 min by
separation of the cells from the buffer by rapid centrifugation at high speed through
silicone oil [22]. The uptake times were based on kinetic evaluations showing that
uptake is complete after 5 min [22]. The centrifugation tubes were frozen in liquid
nitrogen and cut to separate the cell pellet from the silicone oil and assay buffer
layers. The cell pellet was lysed. Scintillation fluid was added, and radioactivity was
counted on a beta-counter. Nonspecific uptake was determined for each experiment in
the presence of 10 M fluoxetine for SERT cells, 10 M nisoxetine for NET cells,
6
and 10 M mazindol for DAT cells and subtracted from the total counts to yield
specific uptake (100%). Nonspecific uptake was < 15% of total uptake. The data were
fit by non-linear regression to variable-slope sigmoidal dose-response curves, and
IC50 values were calculated using Prism (GraphPad, San Diego, CA, USA).
DAT/SERT ratios were calculated as 1/DAT IC50:1/SERT IC50. The DAT/SERT ratio
is considered useful to predict the characteristics of the psychoactive effects of novel
psychoactive substances [4, 23-25]. Higher relative potency at the DAT may indicate
a higher abuse potential while relatively increased activity on the 5-HT system is
linked to reduced abuse potential and more MDMA-like psychotropic effects [25].
Stimulant amphetamines such as methamphetamine exhibit a DAT/SERT ratio >10,
while MDMA and other substances with MDMA-like psychotropic effects exhibit a
DAT/SERT ratio close to 0.1 [4, 26].
2.3. Transporter-mediated monoamine release
We studied the effects of 100 µM of the test compounds on transportermediated NE, 5-HT, and DA efflux in HEK 293 cells that overexpressed the
respective human monoamine transporter as previously reported in detail [4]. Briefly,
we preloaded the cells by incubating SERT cells with 10 nM [ 3H]5-HT, DAT cells
with 10 nM [3H]DA and 1 µM unlabeled DA, and NET cells with 10 nM [ 3H]NE and
10 µM unlabeled NE for 20 min. The cells were then washed twice, and release was
induced by adding 1000 µl of release buffer that contained the test compounds at
concentrations of 100 µM. We incubated the SERT and DAT cells for 15 min and
NET cells for 45 min at 37°C by shaking at 300 rotations per minute on a rotary
shaker. The release times were based on kinetic evaluation of the release-over-time
curves for MDMA. After 15 min for [3H]5-HT and [3H]DA and 45 min for [3H]NE, a
sufficient amount of radioactivity was released to allow for comparisons with the
7
control conditions. We then stopped release by removing the buffer and gently
washing the cells twice with cold buffer. We quantified the radioactivity that
remained in the cells. Nonspecific “pseudo-efflux,” which arises from substrate that
diffuses out of the cells and reuptake inhibition [27, 28], was assessed for each
experiment using the transporter inhibitors nisoxetine (NET cells), citalopram (SERT
cells), and mazindol (DAT cells) at 10 µM as negative control conditions. We then
used analysis of variance followed by Dunnett’s test to compare test drug-induced
monoamine release with nisoxetine, citalopram, and mazindol (negative controls).
Compounds that induced significantly higher maximal monoamine efflux compared
with the respective transporter inhibitors, which induced slight nonspecific release,
were considered monoamine releasers. MDMA was used as a positive control
condition in each experiment. Previously published data on cathinones [6] were
obtained from the same experiments and tested along-side with the drugs described
here. Therefore the data on MDMA are the same as previously published [6] and data
on cathinones [6] can be compared with those obtained with the data shown here. All
of the conditions were normalized to radioactive counts of the assay buffer control
condition. The assays allowed qualitative classification of a drug as a releaser or nonreleaser at 100 µM, but not quantitative comparisons between transporters.
2.4. Radioligand binding assays
The radioligand binding assays were performed as described previously [4, 22,
29]. Briefly, membrane preparations of HEK 293 cells (Invitrogen, Zug, Switzerland)
that overexpress the respective transporters [21] or receptors (human genes, with the
exception of TAAR1 receptors that were rat/mouse; [29]) were incubated with the
radiolabeled selective ligands at concentrations equal to Kd, and ligand displacement
8
by the compounds was measured. Specific binding of the radioligand to the target
receptor was defined as the difference between the total binding and nonspecific
binding determined in the presence of selected competitors in excess. The following
radioligands and competitors, respectively, were used: N-methyl-[3H]-nisoxetine and
indatraline (NET), [3H]citalopram and indatraline (SERT), [3H]WIN35,428 and
indatraline (DAT), [3H]8-hydroxy-2-(di-n-propylamino)tetralin and indatraline (5HT1A receptor), [3H]ketanserin and spiperone (5-HT2A receptor), [3H]mesulergine and
mianserin (5-HT2C receptor), [3H]prazosin and risperidone (1 adrenergic receptor),
[3H]rauwolscine and phentolamine (2 adrenergic receptor), [3H]SCH 23390 and
butaclamol (DA D1 receptor), [3H]spiperone and spiperone (DA D2 and D3 receptors),
[3H]pyrilamine and clozapine (histaminergic H1 receptor), and [3H]RO5166017 and
RO5166017 (TAAR1). IC50 values were determined by calculating nonlinear
regression curves for a one-site model using three to five independent 10-point
concentration-response curves for each compound. Ki (affinity) values, which
correspond to the dissociation constants, were determined using the Cheng-Prusoff
equation. Similarly obtained data on MDMA has previously been published [4, 6].
3. Results
3.1. Monoamine uptake transporter inhibition
The effects of the test compounds on monoamine transporter function are
presented in Fig. 2. The corresponding IC50 values for monoamine transport inhibition
and DAT/SERT inhibition ratios are shown in Table 1. With the exception of m-CPP
and TFMPP, all of the tested compounds inhibited NET with IC50 values of 0.1 - 1
µM. For comparison, clinically used NET inhibitors such as reboxetine, indatraline,
9
or duloxetine are slightly more potent and inhibited NET with IC50 values of 0.036,
0.43 and 0.126 µM in the same or similar assays [22].
DAT and SERT inhibition potencies varied considerably, resulting in a wide range of
DAT/SERT inhibition ratios. Both ring-substituted aminoindanes, 5-IAI and MDAI,
and both phenyl-piperazines, m-CPP and TFMPP, preferentially inhibited the SERT
over the DAT, similar to MDMA [4, 6]. The pipradrol derivatives D2PM, 2-DPMP,
and methylphenidate were all considerably more potent DAT vs. SERT inhibitors. 2AI and BZP showed only low potency as DAT or SERT inhibitors (IC 50 values > 10
µM).
3.2. Transporter-mediated monoamine release
The effects of the test compounds on the transporter-mediated release of NE,
DA, and 5-HT from transmitter-preloaded cells are depicted in Fig. 3. As expected,
MDMA induced significant efflux of NE, DA, and 5-HT compared with the
nonspecific “release” observed with the pure uptake inhibitors nisoxetine, mazindol,
and citalopram, respectively. The aminoindanes were releasers of at least one
monoamine. 5-IAI released 5-HT and DA. MDAI released 5-HT and NE. 2-AI
released NE and DA. Among the piperazines, BZP released DA, m-CPP released 5HT, and TFMPP did not induce the efflux of any monoamine. None of the pipradrol
derivatives or methylphenidate was a substrate releaser.
3.3. Binding affinities
Table 2 shows the binding profiles of the test compounds expressed as the
potencies of the compounds (Ki) to inhibit radioligand binding to the NET, DAT, and
SERT and different monoamine receptors. Among the aminoindanes, the binding
10
profile of MDAI was similar to MDMA [4, 6], whereas 5-IAI exhibited
submicromolar affinities (< 1 M) for the 5-HT1A, 5-HT2A, α2A, and D3 receptors. In
contrast to MDMA [4, 6], the phenylpiperazines m-CPP and TFMPP showed
submicromolar (< 1 M) binding to many monoamine receptors, including the 5HT1A, 5-HT2A, 5-HT2C, α2A, and D1-3 receptors. The pipradrol derivatives and
methylphenidate potently bound to the DAT, but not to any other sites. The
aminoindanes, and the phenylpiperazines showed affinity for the rat and mouse
TAAR1, similar to MDMA [4, 6]. Binding potencies at the monoamine transporters
were typically weak, except for the high-affinity (< 100 nM) binding of the pipradrol
derivatives at the DAT.
4. Discussion
All of the novel substances characterized in the present study interacted with
the monoamine transporters. High potency of a compound to inhibit the
catecholamine transporter NET and DAT in vitro is associated with greater
psychostimulant potency in humans [4]. These compounds typically exhibit a
DAT/SERT ratio > 1 and a high abuse potential [4]. Predominant drug activity at the
SERT [22] and a DAT/SERT inhibition ratio of typically 0.01 - 0.1 are expected to
result in subjective drug effects similar to those of MDMA or other empathogens [4,
6]. These serotonergic compounds produce subjective well-being and enhanced
empathy and sociability in humans without marked psychostimulation [5, 30].
Additionally, compounds which predominantly act on SERT and NET [6] have been
associated with 5-HT syndrome, hyperthermia and resulting organ failure.
Furthermore, compounds which act as monoamine releasers (i.e., MDMA or
methamphetamine [4, 6]) enter the intracellular space via the transporter. In contrast
11
to pure transporter blockers (i.e., cocaine), monoamine releasers are expected to have
more subsequent intracellular pharmacological and neurotoxic consequences [31, 32].
The in vitro pharmacological profiles of the compounds studied herein may be
useful to predict the clinical effects according to the associations noted above. The
profiles can also be compared with those of cocaine and a series of recreationally used
amphetamine and cathinone derivatives previously characterized using the same in
vitro assays [4, 6].
4.1. Aminoindanes
The aminoindanes 5-IAI and MDAI preferentially inhibited the NET and
SERT and less potently inhibited the DAT, similar to MDMA [4, 6], but with
approximately two-fold lower potency. 5-IAI and MDAI released 5-HT through the
SERT, similar to MDMA. MDAI also shared the NE-releasing property and receptor
binding profile of MDMA [4, 6]. Similar inhibitory effects of 5-IAI and MDAI on
human monoamine transporters have recently been shown [7], but no comparable data
on monoamine release are available. In contrast to the human transporter studies, both
MDAI and 5-IAI were relatively more potent SERT and DAT vs. NET inhibitors in
rat brain synaptosomes [33]. Similar to our data, MDAI released 5-HT, but not DA,
and 5-IAI released both 5-HT and DA from rat brain synaptosomes [33]. 5-IAI and
MDAI substituted for MDMA in drug discrimination studies [20, 34], but were
considered less neurotoxic than MDMA [20, 34, 35]. This profile may increase the
popularity of these aminoindanes [13]. The comparable monoamine transporter
inhibition and release profile to MDMA [4, 6] would predict that MDAI has very
similar subjective effects to MDMA, and this is supported by user reports [12, 36].
Rare severe complications include serotonin syndrome and hyperthermia [36], also
12
similar to MDMA. In contrast to MDAI and MDMA [4, 6], 5-IAI exhibited relevant
binding to 5-HT receptors, including the 5-HT2A receptor that is implicated in the
action of hallucinogens [37]. 5-IAI is also considered a less potent MDMA substitute,
but dysphoria, anxiety, and hallucinations have also been reported [13]. In contrast to
the substituted aminoindanes, 2-AI selectively inhibited the NET, but not the DAT or
SERT. This profile is relatively similar to BZP in the present study, but most other
amphetamines also typically more potently inhibit the DAT [4, 6]. 2-AI also released
NE and DA. No comparable data on the pharmacology of 2-AI have been reported.
Based on the profile in the present study, 2-AI likely has only mild psychostimulant
effects in humans.
4.2. Piperazines
Although piperazines have been widely used since the 1990s, and their
pharmacology and toxicology have been reviewed [14, 38-41], only few and
conflicting original data are available on their pharmacological mechanism. In the
present study, BZP inhibited the NET and released DA. Early studies in rats found
that BZP inhibits the uptake of not only NE and DA, but also 5-HT [42], which is
very inconsistent with our data obtained with human transporters and recent rat
studies [43]. Similar to the present study, BZP produced the transporter-mediated
release of DA, but not 5-HT from rat synaptosomes in vitro [43]. BZP enhanced
electrically induced NE release from rabbit arteries [44], likely reflecting its NETinhibiting properties. BZP also induced a robust increase in extracellular DA in vivo,
but only weakly increased 5-HT dialysate levels at higher doses [43]. Speculations
that BZP may act as an α2-adrenergic antagonist [44] in humans seem unlikely, given
the lack of binding to this and other monoamine receptors in the present study. We
13
also did not confirm the results of an early rat study that reported the 5-HT
antagonistic properties of BZP [45]. Thus, our data indicate that BZP is an indirect
DA and NE agonist without serotonergic properties. In animals, BZP induced place
preference in rats [46] and was self-administered in monkeys, and it substituted for
amphetamine in discrimination studies [47]. In humans, 100 mg BZP produced
subjective and cardiostimulant effects similar to 7.5-10 mg amphetamine [48, 49],
consistent with the five- to 10-fold lower potency of BZP at the NET and DAT
compared with amphetamine [4]. In healthy women, a dose of 200 mg BZP produced
cardiostimulant and subjective effects that were considered similar to those generally
seen with stimulants [50], but a direct comparison with other compounds is lacking.
The clinical toxicity of BZP mainly includes hallucinations, agitation, seizures, and
hyperthermia [40]. Drug users associated more unpleasant effects and hallucinations
with BZP than with MDMA [51]. The phenylpiperazines TFMPP and m-CPP
preferentially inhibited the SERT as previously reported [52, 53]. TFMPP did not act
as a 5-HT releaser, and m-CPP only weakly released 5-HT in the present study.
SERT-mediated 5-HT release from rat brain synaptosomes or slices has previously
been documented for both TFMPP [43, 54] and m-CPP [54-56]. Further studies are
needed to determine whether the phenylpiperazines differentially interact with the
human and rat SERT and whether additional proteins present in the synaptosomal
preparations, but not in transfected HEK-293 cells may explain this discrepancy. Also
needing clarification is the extent to which the in vivo serotonergic action of m-CPP is
linked to 5-HT release vs. uptake inhibition. In fact, m-CPP has been shown to bind
more potently to the SERT than the 5-HT releaser fenfluramine and not to induce
long-term 5-HT depletion [53], which are both characteristics of SERT inhibitors
rather than 5-HT releasers. m-CPP did not release DA or NE from synaptosomes [56],
14
consistent with our data. Furthermore, we confirmed the previously documented
binding of TFMPP and m-CPP to rat 5-HT receptors [52] for the human 5-HT1A, 5HT2A, and 5-HT2C receptors. In rhesus monkeys, TFMPP has no reinforcing
properties and does not maintain responding for amphetamine [47]. Additionally,
TFMPP reduced the self-administration of BZP and responding for cocaine [47].
Altogether, the preclinical data indicate that both m-CPP and TFMPP are both
indirect and direct serotonergic agonists without relevant dopaminergic activity.
However, their precise interaction with the human SERT and the nature of their
serotonergic action in vivo require further investigations. m-CPP is frequently found
in Ecstasy pills as a replacement for MDMA [57, 58]. Recreational users consider mCPP to have less desirable psychotropic effects and more adverse effects, including
nausea, compared with MDMA [51, 58]. In experimental studies in humans, m-CPP
produced mostly dysphoria, weakness, dizziness, anxiety, and nausea [59-61] and
less, if any, positive subjective effects, drug liking, and cardiovascular stimulation in
direct comparisons with MDMA [62]. The lower clinical potency and efficacy of mCPP compared with MDMA may be explained by its lower potency as a DAT and
NET inhibitor compared with MDMA [4, 6] or by its lower efficacy to induce the
release of 5-HT. The effects of TFMPP have not been directly compared with other
psychoactive substances in humans. TFMPP alone produced moderate dysphoria and
amphetamine-type stimulation [63], but not the usual increases in euphoria seen after
MDMA administration [64] using the same psychometric scale. Unsurprisingly,
therefore, the use of TFMPP alone does not appear to be common [51]. In contrast,
BZP in combination with either m-CPP or TFMPP is sometimes sold as Ecstasy [16,
41]. Because BZP releases DA, and m-CPP and TFMPP are direct and indirect
serotonergic agonists, their combination would be expected to mimic the psychoactive
15
profile of MDMA. In rats, the combination of BZP and TFMPP elevated brain DA
and 5-HT levels similarly to MDMA [43]. In humans, the combination of BZP and
TFMPP produced stimulation and “good” drug effects, but no euphoria [65]. The
BZP-TFMPP combination was not well tolerated at higher doses and frequently
produced agitation, anxiety, hallucinations, and vomiting [66], whereas these adverse
effects were infrequently observed after MDMA administration in a similar laboratory
study [67]. As noted above, the BZP-TFMPP combination has reduced reinforcing
properties compared with BZP alone [47], consistent with the abuse-lowering effects
of 5-HT.
4.3. Pipradrol derivatives
D2PM and 2-DPMP were selective catecholamine transporter inhibitors
without
transporter-mediated
substrate-releasing
properties,
similar
to
methylphenidate. 2-DPMP was a DAT/NET inhibitor that was equally potent to
methylphenidate, whereas D2PM was less potent. Consistent with our findings, 2DPMP has been previously shown to inhibit the human NET and DAT, but not SERT
[7], and block the uptake of DA and NE into synaptic rat brain vesicles [68, 69]. 2DPMP also blocked NE uptake into rabbit aortic strips, but did not induce NE release
[70], also consistent with our results. Compared with classic stimulants, 2-DPMP was
a 10-fold more potent DAT blocker than cocaine [4]. Consistent with the greater
DAT-inhibiting potency, 2-DPMP also more potently increased electrically evoked
DA release in rat brain slices compared with cocaine [71]. We found no other data on
the monoamine uptake and releasing properties of D2PM. The pharmacological
profile of the pipradrol derivatives was very similar to the pyrovalerone cathinones
MDPV and naphyrone that were characterized in the same assays [4], although
16
naphyrone also inhibits the SERT. MDPV and naphyrone rather than 2-DPMP have
been found in some samples of “ivory wave” [72]. Similar to MDPV [4] and
naphyrone [73], 2-DPMP and D2PM are highly lipophilic. Compared with
methylphenidate, 2-DPMP lacks polar groups that are typically targeted by metabolic
enzymes, resulting in a longer half-life [74, 75]. The clinical toxicity of 2-DPMP and
D2PM is long-lasting (24-72 h) and involves sympathomimetic stimulation and
predominantly psychiatric symptoms, including agitation, hallucinations, and
insomnia [17, 18]. Altogether, the pipradrol derivatives are potent and selective
catecholamine uptake inhibitors, consistent with their potent and prolonged
psychostimulant actions. The pharmacological profile is also likely associated with
high abuse liability and an increased risk of psychiatric complications.
4.4. TAAR1 binding
The aminoindanes and phenylpiperazines, but not BZP or pipradrol derivatives,
exhibited potent TAAR1 binding affinity comparable to MDMA [4, 6]. In the present
series, all of the serotonergic compounds also bound TAAR1, whereas the affinity for
TAAR1 has previously been documented for amphetamine and methamphetamine [4],
which only weakly interact with the SERT. Drug activity at the SERT and TAAR 1 are
both considered to counteract the abuse liability associated with dopaminergic drug
properties. Higher serotonergic vs. dopaminergic activity has been associated with a
lower abuse potential of a drug [4, 23-25]. Amphetamines such as MDMA and
methamphetamine have been shown to inhibit their own neurochemical and
locomotor stimulant effects via TAAR1 activation [76]. The lack of serotonergic
activity and lack of TAAR1-mediated “auto-inhibition” in particular with the
pipradrol derivatives may contribute to the more stimulant-like and addictive
17
properties of this class of designer compounds compared with classic amphetamines,
including MDMA [4].
4.5. Limitations
Knowing the mechanism of action of novel compounds in vitro helps to predict
potential clinical effects and abuse potential. However, many additional factors also
play a role such as brain tissue penetration and pharmacokinetics which need to be
further assessed in vivo.
Conclusion
In summary, the aminoindanes, 5-IAI and MDAI inhibited the SERT and
released 5-HT, similar to MDMA [4]. Among the piperazines, BZP interacted with
the DAT and NET, and m-CPP and TFMPP interacted with the SERT and
serotonergic receptors. The pipradrol derivatives were all potent and selective
catecholamine transporter blockers without substrate-releasing properties. The
predominant actions of D2PM and 2-DPMP on DAT likely predict a high abuse
liability. Further studies are needed to determine potential differences between data
obtained with human or rodent transporter studies and to further validate predictions
of clinical effects based on such data.
Conflict of interest
The authors do not have any conflicts of interest to declare for this work.
Acknowledgements
18
We thank S. Chaboz and B. Wolf for technical assistance and Prof. A. Pfaltz for
providing support for the synthesis of MDAI. This work was supported by the Swiss
National Science Foundation (no. 320030_149493/1), the Federal Office of Public
Health (no. 13.006497), and the Translational Medicine Hub Innovation Fund of F.
Hoffmann-La Roche and the University of Basel.
References
[1]
Dargan PI, Wood DM. Novel psychoactive substances: classification, pharmacology
and toxicology. Amsterdam, Elsevier Academic Press, 2013.
[2]
Hill SL, Thomas SH. Clinical toxicology of newer recreational drugs. Clin Toxicol
(Phila) 2011;49:705-19.
[3]
Dal Cason TA, Young R, Glennon RA. Cathinone: an investigation of several N-alkyl
and methylenedioxy-substituted analogs. Pharmacol Biochem Behav 1997;58:110916.
[4]
Simmler L, Buser T, Donzelli M, Schramm Y, Dieu LH, Huwyler J, et al.
Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol
2013;168:458-70.
[5]
Hysek CM, Schmid Y, Simmler LD, Domes G, Heinrichs M, Eisenegger C, et al.
MDMA enhances emotional empathy and prosocial behavior. Soc Cogn Affect
Neurosci 2013 (in press).
[6]
Simmler LD, Rickli A, Hoener MC, Liechti ME. Monoamine transporter and receptor
interaction profiles of a new series of designer cathinones. Neuropharmacology
2014;79:152-60.
[7]
Iversen L, Gibbons S, Treble R, Setola V, Huang XP, Roth BL. Neurochemical
profiles of some novel psychoactive substances. Eur J Pharmacol 2013;700:147-51.
19
[8]
Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, et al.
Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a
principal
constituent
of
psychoactive
"bath
salts"
products.
Neuropsychopharmacology 2013;38:552-62.
[9]
Lopez-Arnau R, Martinez-Clemente J, Pubill D, Escubedo E, Camarasa J.
Comparative neuropharmacology of three psychostimulant cathinone derivatives:
butylone, mephedrone and methylone. Br J Pharmacol 2012;167:407-20.
[10]
Eshleman AJ, Wolfrum KM, Hatfield MG, Johnson RA, Murphy KV, Janowsky A.
Substituted methcathinones differ in transporter and receptor interactions. Biochem
Pharmacol 2013;85:1803-15.
[11]
Sainsbury PD, Kicman AT, Archer RP, King LA, Braithwaite RA. Aminoindanes:
the next wave of "legal highs"? Drug Test Anal 2011;3:479-82.
[12]
Gallagher CT, Assi S, Stair JL, Fergus S, Corazza O, Corkery JM, et al. 5,6Methylenedioxy-2-aminoindane: from laboratory curiosity to "legal high". Hum
Psychopharmacol 2012;27:106-12.
[13]
Coppola M, Mondola R. 5-Iodo-2-aminoindan (5-IAI): Chemistry, pharmacology,
and toxicology of a research chemical producing MDMA-like effects. Toxicol Lett
2013;218:24-9.
[14]
Monteiro MS, Bastos Mde L, Guedes de Pinho P, Carvalho M. Update on 1benzylpiperazine (BZP) party pills. Arch Toxicol 2013;87:929-47.
[15]
Wilkins
C,
Sweetsur
P,
Girling
M.
Patterns
of
benzylpiperazine/trifluoromethylphenylpiperazine party pill use and adverse effects
in a population sample in New Zealand. Drug Alcohol Rev 2008;27:633-9.
[16]
Wood DM, Button J, Lidder S, Ramsey J, Holt DW, Dargan PI. Dissociative and
sympathomimetic
toxicity
associated
with
recreational
use
of
1-(3-
trifluoromethylphenyl) piperazine (TFMPP) and 1-benzylpiperzine (BZP). J Med
Toxicol 2008;4:254-7.
20
[17]
Murray DB, Potts S, Haxton C, Jackson G, Sandilands EA, Ramsey J, et al. "Ivory
wave" toxicity in recreational drug users; integration of clinical and poisons
information services to manage legal high poisoning. Clin Toxicol 2012;50:108-13.
[18]
Wood DM, Puchnarewicz M, Johnston A, Dargan PI. A case series of individuals
with analytically confirmed acute diphenyl-2-pyrrolidinemethanol (D2PM) toxicity.
Eur J Clin Pharmacol 2012;68:349-53.
[19]
Corkery JM, Elliott S, Schifano F, Corazza O, Ghodse AH. 2-DPMP
(desoxypipradrol, 2-benzhydrylpiperidine, 2-phenylmethylpiperidine) and D2PM
(diphenyl-2-pyrrolidin-2-yl-methanol, diphenylprolinol): A preliminary review. Prog
Neuropsychopharmacol Biol Psychiatry 2012;39:253-8.
[20]
Nichols DE, Brewster WK, Johnson MP, Oberlender R, Riggs RM. Nonneurotoxic
tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA). J Med
Chem 1990;33:703-10.
[21]
Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of
antidepressants and related compounds at human monoamine transporters. Eur J
Pharmacol 1997;340:249-58.
[22]
Hysek CM, Simmler LD, Nicola V, Vischer N, Donzelli M, Krähenbühl S, et al.
Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a
randomized placebo-controlled laboratory study. PLoS One 2012;7:e36476.
[23]
Baumann MH, Clark RD, Woolverton WL, Wee S, Blough BE, Rothman RB. In vivo
effects of amphetamine analogs reveal evidence for serotonergic inhibition of
mesolimbic dopamine transmission in the rat. J Pharmacol Exp Ther 2011;337:21825.
[24]
Rothman RB, Baumann MH. Balance between dopamine and serotonin release
modulates behavioral effects of amphetamine-type drugs. Ann N Y Acad Sci
2006;1074:245-60.
21
[25]
Wee S, Anderson KG, Baumann MH, Rothman RB, Blough BE, Woolverton WL.
Relationship between the serotonergic activity and reinforcing effects of a series of
amphetamine analogs. J Pharmacol Exp Ther 2005;313:848-54.
[26]
Baumann MH, Ayestas MA, Jr., Partilla JS, Sink JR, Shulgin AT, Daley PF, et al.
The designer methcathinone analogs, mephedrone and methylone, are substrates for
monoamine transporters in brain tissue. Neuropsychopharmacology 2012;37:1192203.
[27]
Scholze P, Zwach J, Kattinger A, Pifl C, Singer EA, Sitte HH. Transporter-mediated
release: a superfusion study on human embryonic kidney cells stably expressing the
human serotonin transporter. J Pharmacol Exp Ther 2000;293:870-8.
[28]
Rosenauer R, Luf A, Holy M, Freissmuth M, Schmid R, Sitte HH. A combined
approach using transporter-flux assays and mass spectrometry to examine
psychostimulant street drugs of unknown content. ACS Chem Neurosci 2013;4:18290.
[29]
Revel FG, Moreau JL, Gainetdinov RR, Bradaia A, Sotnikova TD, Mory R, et al.
TAAR1
activation
modulates
monoaminergic
neurotransmission,
preventing
hyperdopaminergic and hypoglutamatergic activity. Proc Natl Acad Sci U S A
2011;108:8485-90.
[30]
Hysek CM, Simmler LD, Schillinger N, Meyer N, Schmid Y, Donzelli M, et al.
Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA
administered alone and in combination. Int J Neuropsychopharmacol 2013 (in press).
[31]
Fleckenstein AE, Gibb JW, Hanson GR. Differential effects of stimulants on
monoaminergic transporters: pharmacological consequences and implications for
neurotoxicity. Eur J Pharmacol 2000;406:1-13.
[32]
Baumann MH, Wang X, Rothman RB. 3,4-Methylenedioxymethamphetamine
(MDMA) neurotoxicity in rats: a reappraisal of past and present findings.
Psychopharmacology 2007;189:407-24.
22
[33]
Johnson MP, Conarty PF, Nichols DE. [3H]monoamine releasing and uptake
inhibition
properties
of
3,4-methylenedioxymethamphetamine
and
p-
chloroamphetamine analogues. Eur J Pharmacol 1991;200:9-16.
[34]
Nichols DE, Johnson MP, Oberlender R. 5-Iodo-2-aminoindan, a nonneurotoxic
analogue of p-iodoamphetamine. Pharmacol Biochem Behav 1991;38:135-9.
[35]
Johnson MP, Huang XM, Nichols DE. Serotonin neurotoxicity in rats after combined
treatment with a dopaminergic agent followed by a nonneurotoxic 3,4methylenedioxymethamphetamine (MDMA) analogue. Pharmacol Biochem Behav
1991;40:915-22.
[36]
Corkery JM, Elliott S, Schifano F, Corazza O, Ghodse AH. MDAI (5,6methylenedioxy-2-aminoindane;
amine;
'sparkle';
'mindy')
6,7-dihydro-5H-cyclopenta[f][1,3]benzodioxol-6-
toxicity:
a
brief
overview
and
update.
Hum
Psychopharmacol 2013;28:345-55.
[37]
Nichols DE. Hallucinogens. Pharmacol Ther 2004;101:131-81.
[38]
Schep LJ, Slaughter RJ, Vale JA, Beasley DM, Gee P. The clinical toxicology of the
designer "party pills" benzylpiperazine and trifluoromethylphenylpiperazine. Clin
Toxicol 2011;49:131-41.
[39]
European Monitoring Centre for Drugs and Drug Addiction. Report on the risk
assessment of BZP in the framework of the Council decision on new psychoactive
substances. Issue 8. Lisbon: European Monitoring Centre for Drugs and Drug
Addiction; 2009.
[40]
Gee P, Gilbert M, Richardson S, Moore G, Paterson S, Graham P. Toxicity from the
recreational use of 1-benzylpiperazine. Clin Toxicol 2008;46:802-7.
[41]
Sheridan J, Butler R, Wilkins C, Russell B. Legal piperazine-containing party pills: a
new trend in substance misuse. Drug Alcohol Rev 2007;26:335-43.
[42]
Tekes K, Tothfalusi L, Malomvolgyi B, Herman F, Magyar K. Studies on the
biochemical mode of action of EGYT-475, a new antidepressant. Pol J Pharmacol
Pharm 1987;39:203-11.
23
[43]
Baumann MH, Clark RD, Budzynski AG, Partilla JS, Blough BE, Rothman RB. Nsubstituted piperazines abused by humans mimic the molecular mechanism of 3,4methylenedioxymethamphetamine
(MDMA,
or
'Ecstasy').
Neuropsychopharmacology 2005;30:550-60.
[44]
Magyar K, Fekete MI, Tekes K, Torok TL. The action of trelibet, a new
antidepressive agent on [3H]noradrenaline release from rabbit pulmonary artery. Eur
J Pharmacol 1986;130:219-27.
[45]
Malomvolgyi B, Tothfalusi L, Tekes K, Magyar K. Comparison of serotonin
agonistic and antagonistic activities of a new antidepressant agent Trelibet (EGYT475) and its metabolite EGYT-2760 on isolated rat fundus. Acta Physiol Hung
1991;78:201-9.
[46]
Meririnne E, Kajos M, Kankaanpaa A, Seppala T. Rewarding properties of 1benzylpiperazine, a new drug of abuse, in rats. Basic Clin Pharmacol Toxicol
2006;98:346-50.
[47]
Fantegrossi WE, Winger G, Woods JH, Woolverton WL, Coop A. Reinforcing and
discriminative
stimulus
effects
of
1-benzylpiperazine
and
trifluoromethylphenylpiperazine in rhesus monkeys. Drug Alcohol Depend
2005;77:161-8.
[48]
Bye C, Munro-Faure AD, Peck AW, Young PA. A comparison of the effects of 1benzylpiperazine and dexamphetamine on human performance tests. Eur J Clin
Pharmacol 1973;6:163-9.
[49]
Campbell H, Cline W, Evans M, Lloyd J, Peck AW. Proceedings: Comparison of the
effects of dexamphetamine and 1-benzylpiperazine in former addicts. Br J Pharmacol
1972;44:369P-70P.
[50]
Lin JC, Bangs N, Lee H, Kydd RR, Russell BR. Determining the subjective and
physiological
effects
of
BZP
on
2009;207:439-46.
24
human
females.
Psychopharmacology
[51]
Brunt TM, Koeter MW, Niesink RJ, van den Brink W. Linking the pharmacological
content of ecstasy tablets to the subjective experiences of drug users.
Psychopharmacology 2012;220:751-62.
[52]
Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor and
transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp
Ther 1997;283:1305-22.
[53]
Baumann
MH,
Ayestas
MA,
Dersch
CM,
Rothman
RB.
1-(m-
chlorophenyl)piperazine (mCPP) dissociates in vivo serotonin release from long-term
serotonin depletion in rat brain. Neuropsychopharmacology 2001;24:492-501.
[54]
Auerbach SB, Kamalakannan N, Rutter JJ. TFMPP and RU24969 enhance serotonin
release from rat hippocampus. Eur J Pharmacol 1990;190:51-7.
[55]
Pettibone DJ, Williams M. Serotonin-releasing effects of substituted piperazines in
vitro. Biochem Pharmacol 1984;33:1531-5.
[56]
Rothman RB, Baumann MH. Therapeutic and adverse actions of serotonin transporter
substrates. Pharmacol Ther 2002;95:73-88.
[57]
Brunt TM, Poortman A, Niesink RJ, van den Brink W. Instability of the ecstasy
market and a new kid on the block: mephedrone. J Psychopharmacol 2011;25:1543-7.
[58]
Bossong MG, Brunt TM, Van Dijk JP, Rigter SM, Hoek J, Goldschmidt HM, et al.
mCPP: an undesired addition to the ecstasy market. J Psychopharmacol
2010;24:1395-401.
[59]
Broocks A, Briggs NC, Pigott TA, Hill JL, Canter SK, Tolliver TJ, et al. Behavioral,
physiological and neuroendocrine responses in healthy volunteers to mchlorophenylpiperazine (m-CPP) with and without ondansetron pretreatment.
Psychopharmacology 1997;130:91-103.
[60]
Feuchtl A, Bagli M, Stephan R, Frahnert C, Kolsch H, Kuhn KU, et al.
Pharmacokinetics
of
m-chlorophenylpiperazine
after
intravenous
and
oral
administration in healthy male volunteers: implication for the pharmacodynamic
profile. Pharmacopsychiatry 2004;37:180-8.
25
[61]
Gijsman HJ, Van Gerven JM, Tieleman MC, Schoemaker RC, Pieters MS, Ferrari
MD, et al. Pharmacokinetic and pharmacodynamic profile of oral and intravenous
meta-chlorophenylpiperazine in healthy volunteers. J Clin Psychopharmacol
1998;18:289-95.
[62]
Tancer M, Johanson CE. Reinforcing, subjective, and physiological effects of
MDMA in humans: a comparison with d-amphetamine and mCPP. Drug Alcohol
Depend 2003;72:33-44.
[63]
Jan RK, Lin JC, Lee H, Sheridan JL, Kydd RR, Kirk IJ, et al. Determining the
subjective effects of TFMPP in human males. Psychopharmacology 2010;211:34753.
[64]
Hysek CM, Domes G, Liechti ME. MDMA enhances "mind reading" of positive
emotions and impairs "mind reading" of negative emotions. Psychopharmacology
2012;222:293-302.
[65]
Lin JC, Jan RK, Lee H, Jensen MA, Kydd RR, Russell BR. Determining the
subjective and physiological effects of BZP combined with TFMPP in human males.
Psychopharmacology 2011;214:761-8.
[66]
Thompson I, Williams G, Caldwell B, Aldington S, Dickson S, Lucas N, et al.
Randomised double-blind, placebo-controlled trial of the effects of the "party pills"
BZP/TFMPP alone and in combination with alcohol. J Psychopharmacol
2010;24:1299-308.
[67]
Liechti ME, Gamma A, Vollenweider FX. Gender differences in the subjective
effects of MDMA. Psychopharmacology 2001;154:161-8.
[68]
Ferris RM, Tang FL. Comparison of the effects of the isomers of amphetamine,
methylphenidate and deoxypipradrol on the uptake of l-[3H]norepinephrine and
[3H]dopamine by synaptic vesicles from rat whole brain, striatum and hypothalamus.
J Pharmacol Exp Ther 1979;210:422-8.
[69]
Ferris RM, Tang FL, Maxwell RA. A comparison of the capacities of isomers of
amphetamine, deoxypipradrol and methylphenidate to inhibit the uptake of tritiated
26
catecholamines into rat cerebral cortex slices, synaptosomal preparations of rat
cerebral cortex, hypothalamus and striatum and into adrenergic nerves of rabbit aorta.
J Pharmacol Exp Ther 1972;181:407-16.
[70]
Maxwell RE, Chaplin E, Eckhardt SB, Soares JR, Hite G. Conformational similarities
between molecular models of phenethylamine and of potent inhibitors of the uptake
of tritiated norepinephrine by adrenergic nerves in rabbit aorta. J Pharmacol Exp Ther
1970;173:158-65.
[71]
Davidson C, Ramsey J. Desoxypipradrol is more potent than cocaine on evoked
dopamine efflux in the nucleus accumbens. J Psychopharmacol 2012;26:1036-41.
[72]
Durham M. Ivory wave: the next mephedrone? Emerg Med J 2011;28:1059-60.
[73]
Derungs A, Schietzel S, Meyer MR, Maurer HH, Krahenbuhl S, Liechti ME.
Sympathomimetic toxicity in a case of analytically confirmed recreational use of
naphyrone (naphthylpyrovalerone). Clin Toxicol 2011;49:691-3.
[74]
Coppola M, Mondola R. Research chemicals marketed as legal highs: the case of
pipradrol derivatives. Toxicol Lett 2012;212:57-60.
[75]
Tripod J, Sury E, Hoffmann K. Zentralerregende Wirkung eines neuen
Piperidinderivates [Analeptic effect of a new piperidine derivative]. Experientia
1954;10:261-2.
[76]
Di Cara B, Maggio R, Aloisi G, Rivet JM, Lundius EG, Yoshitake T, et al. Genetic
deletion of trace amine 1 receptors reveals their role in auto-inhibiting the actions of
ecstasy (MDMA). J Neurosci 2011;31:16928-40.
27
Figure Legends
Figure 1. Structures of novel psychoactive substances that mimic the effects of 3,4methylenedioxymethamphetamine (MDMA) or methylphenidate. 2-Aminoindane (2AI), 5-iodo-2-aminoindane (5-IAI), and 5,6-methylenedioxy-2-aminoindane (MDAI)
are recreationally used aminoindanes. Meta-chlorophenylpiparazine (m-CPP),
trifluoromethylphenylpiperazine
(TFMPP),
and
benzylpiperazine
(BZP)
are
piperazines commonly found in pills sold as Ecstasy. Diphenylprolinol (diphenyl-2pyrrolidinemethanol [D2PM]) and desoxypipradrol (2-diphenylmethylpiperidine [2DPMP]) are pipradrol derivatives sold as “legal highs” (“ivory wave”) and
structurally similar to methylphenidate.
28
Figure 2. Monoamine uptake inhibition presented as dose-response curves for the
inhibition of [3H]NE, [3H]DA, and [3H]5-HT into NET-, DAT-, and SERTtransfected HEK 293 cells, respectively. The data are expressed as the mean ± SEM
of 3-4 independent experiments. The data were fit by nonlinear regression. The
corresponding IC50 values are shown in Table 2.
29
Figure 3. Monoamine release induced by 100 µM of test compound. HEK 293 cells
that expressed NET, DAT, and SERT were loaded with [3H]NE, [3H]DA, and [3H]5HT, respectively, washed, and incubated with a high concentration of the compounds
(100 µM). Monoamine release is expressed as the percent reduction of monoamine
cell content compared with vehicle (0% = no release). 100% release would indicate
that all of the monoamine was released from the cells. In such a batch assay, nonreleasing monoamine transporter blockers induce nonspecific “pseudo-efflux”
(dashed line, open bars), which arises from substrate that diffuses out of the cells and
reuptake inhibition. Only compounds that produced significantly more monoamine
efflux (*p < 0.05, ***p < 0.001) compared with the non-releasing uptake inhibitors
30
(negative controls, open bars) nisoxetine (HEK-NET cells), mazindol (HEK-DAT
cells), and citalopram (HEK-SERT cells) were considered monoamine releasers. The
known monoamine releaser MDMA served as a positive control condition for each
experiment. The data are expressed as the mean ± SEM of 3-4 independent
experiments (with negative and positive controls added in each experiment).
31
Table 1 Monoamine uptake transport inhibition
NET
DAT
SERT
DAT/SERT ratio
IC50 [µM] (95% CI)
IC50 [µM] (95% CI)
IC50 [µM] (95% CI)
Ratio (95% CI)
Aminoindans
5-IAI
0.76 (0.60-0.98)
23 (15-35)
2.5 (1.9-3.4)
0.11
MDAI
0.65 (0.50-0.84)
31 (23 - 41)
8.3 (3.2-22)
0.2
2-AI
0.54 (0.42-0.69)
58 (4-905)
> 100
>1
m-CPP
1.67 (1.2-2.4)
31 (25-38)
1.2 (0.9-1.6)
0.04
TFMPP
17.5 (8-39)
> 100
5.2 (3.8-7.0)
< 0.05
0.41 (0.33-0.53)
17 (15-19)
57 (40-81)
3.39
Piparazines
BZP
Pipradrol derivatives
D2PM
0.41 (0.34-0.50)
0.86 (0.74-1.0)
38 (4.7-307)
44.36
2-DPMP
0.14 (0.11-0.18)
0.07 (0.06-0.08)
> 10
> 100
Methylphenidate
0.13 (0.10-0.16)
0.12 (0.09-0.16)
> 100
> 100
Values are means of three to four independent experiments and 95% confidence intervals (CI).
DAT/SERT ratio = 1/DAT IC50 : 1/SERT IC50.
32
Table 2. Monoamine transporter and receptor binding affinities
NET
DAT
SERT
5-HT1A
5-HT2A
5-HT2C
6.3±1.4
5.6±1.5
34±16
0.28±0.08
0.73±0.14
1.2±0.6
a
1A
a
2A
D1
D2
D3
H1
TAAR1rat
TAAR1mouse
>12
1.2±0.6
0.68±0.09
7.4±1.3
0.03±0.01
1.1±0.3
Aminoindanes
5-IAI
>6
0.87±0.33
MDAI
18±2
12±4
22±12
>17
>12
>12
>6
1.36±0.51
>12
>10
14±2
>13
0.57±0.19
1.8±0.1
2-AI
20±7
21±5
>30
4.0±0.8
>12
>12
>6
0.45±0.10
>12
>10
7.6±2.9
>13
0.31±0.09
2.1±0.4
m-CPP
3.0±0.4
5.8±1.4
0.63±0.1
0.14±0.01
0.06±0.02
0.13±0.02
0.52±0.01
0.26±0.02
4.0±0.1
2.2±0.8
2.4±0.6
1.5±0.2
0.05±0.01
6.6±1.1
TFMPP
13±2
>25
1.7±0.04
0.17±0.02
0.06±0.01
0.13±0.01
>6
0.73±0.2
>12
1.4±1.0
0.54±0.05
3.3±0.7
0.38±0.06
2.3±0.6
8.1±0.7
11±4
24±8
> 17
>12
>12
>6
16±5
>12
>10
>16
>13
>10
>10
Piperazines
BZP
Pipradrol derivatives
D2PM
8.2±2.8
0.07±0.03
8.4±1.3
>17
>12
>12
>6
>30
>12
>10
>16
>13
>10
>10
2-DPMP
38±11
0.007±0.001
>30
>17
>12
5.5±0.1
>6
27±9
>12
>10
>16
>13
>10
>10
Methylphenidate
3.3±3.6
0.06±0.01
21±9
NA
>12
NA
>6
20±9
NA
>10
NA
NA
>10
>10
NA, not assessed
Values are Ki given as m M (mean ± SD)
33